1,485
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Quantitative evaluation of liver function with gadoxetic acid enhanced MRI: Comparison among signal intensity-, T1-relaxometry-, and dynamic-hepatocyte-specific-contrast-enhanced MRI- derived parameters

ORCID Icon, , , ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Received 05 Dec 2021, Accepted 16 Jan 2022, Published online: 02 Feb 2022

References

  • Van Beers BE, Pastor CM, Hussain HK. Primovist, eovist: what to expect? J Hepatol. 2012;57(2):421–429.
  • Schwope RB, May LA, Reiter MJ, et al. Gadoxetic acid: pearls and pitfalls. Abdom Imaging. 2015;40(6):2012–2029.
  • Nilsson H, Karlgren S, Blomqvist L, et al. The inhomogeneous distribution of liver function: possible impact on the prediction of post-operative remnant liver function. HPB. 2015;17(3):272–277.
  • Okubo H, Mogami M, Ozaki Y, et al. Liver function test by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging with consideration of intrahepatic regional differences. Hepatogastroenterology. 2013;60(127):1547–1551.
  • Barth BK, Fischer MA, Kambakamba P, et al. Liver-fat and liver-function indices derived from Gd-EOB-DTPA-enhanced liver MRI for prediction of future liver remnant growth after portal vein occlusion. Eur J Radiol. 2016;85(4):843–849.
  • Theilig D, Steffen I, Malinowski M, et al. Predicting liver failure after extended right hepatectomy following right portal vein embolization with gadoxetic acid-enhanced MRI. Eur Radiol. 2019;29(11):5861–5872.
  • Geisel D, Ludemann L, Hamm B, et al. Imaging-Based liver function Tests-Past, Present and Future. Rofo. 2015;187(10):863–871.
  • Tajima T, Takao H, Akai H, et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2010;34(3):362–366.
  • Yamada A, Hara T, Li F, et al. Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology. 2011;260(3):727–733.
  • Brismar TB, Dahlstrom N, Edsborg N, et al. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol. 2009;50(7):709–715.
  • Choi Y, Huh J, Woo DC, et al. Use of gadoxetate disodium for functional MRI based on its unique molecular mechanism. Br J Radiol. 2016;89(1058):20150666.
  • Bae KE, Kim SY, Lee SS, et al. Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI. Dig Dis. 2012;30(6):617–622.
  • Haimerl M, Verloh N, Zeman F, et al. Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: Comparison between signal-intensity-based indices and T1 relaxometry. Sci Rep. 2017;7:43347.
  • Yoneyama T, Fukukura Y, Kamimura K, et al. Efficacy of liver parenchymal enhancement and liver volume to standard liver volume ratio on Gd-EOB-DTPA-enhanced MRI for estimation of liver function. Eur Radiol. 2014;24(4):857–865.
  • Kamimura K, Fukukura Y, Yoneyama T, et al. Quantitative evaluation of liver function with T1 relaxation time index on Gd-EOB-DTPA-enhanced MRI: comparison with signal intensity-based indices. J Magn Reson Imaging. 2014;40(4):884–889.
  • Dahlqvist Leinhard O, Dahlstrom N, Kihlberg J, et al. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur Radiol. 2012;22(3):642–653.
  • de Bazelaire CM, Duhamel GD, Rofsky NM, et al. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology. 2004;230(3):652–659.
  • Nilsson H, Blomqvist L, Douglas L, et al. Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis. Br J Radiol. 2013;86(1026):20120653.
  • Tamada T, Ito K, Higaki A, et al. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol. 2011;80(3):e311-316–e316.
  • Kubota K, Tamura T, Aoyama N, et al. Correlation of liver parenchymal gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid enhancement and liver function in humans with hepatocellular carcinoma. Oncol Lett. 2012;3(5):990–994.
  • Nishie A, Ushijima Y, Tajima T, et al. Quantitative analysis of liver function using superparamagnetic iron oxide- and Gd-EOB-DTPA-enhanced MRI: comparison with technetium-99m galactosyl serum albumin scintigraphy. Eur J Radiol. 2012;81(6):1100–1104.
  • Ozaki K, Matsui O, Kobayashi S, et al. Selective atrophy of the Middle hepatic venous drainage area in hepatitis C-related cirrhotic liver: morphometric study by using multidetector CT. Radiology. 2010;257(3):705–714.
  • Li WX, Zhao XT, Chai WM, et al. Hepatitis B virus-induced liver fibrosis and cirrhosis: the value of liver and spleen volumetry with multi-detector spiral computed tomography. J Dig Dis. 2010;11(4):215–223.
  • Materne R, Smith AM, Peeters F, et al. Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med. 2002;47(1):135–142.
  • Katsube T, Okada M, Kumano S, et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol. 2011;46(4):277–283.
  • Saito K, Ledsam J, Sourbron S, et al. Assessing liver function using dynamic Gd-EOB-DTPA-enhanced MRI with a standard 5-phase imaging protocol. J Magn Reson Imaging. 2013;37(5):1109–1114.
  • Verloh N, Haimerl M, Zeman F, et al. Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 tesla. Eur Radiol. 2014;24(5):1013–1019.